Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells
Small cell lung cancer relies on nonsense‑mediated mRNA decay (NMD) to tolerate its high mutation burden and limit immune detection.
A study reported that small cell lung cancer (SCLC) cells depend on the nonsense‑mediated mRNA decay (NMD) pathway to tolerate their high mutation burden and evade immune detection. Pharmacological inhibition of the NMD kinase SMG1 induces accumulation of mutant proteins, causing tumor‑cell death and enhancing presentation of abnormal peptides on the cell surface, thereby making the tumor recognizable by cytotoxic T cells.
Targeting the NMD pathway, particularly the SMG1 kinase, can transform an immunologically “cold” SCLC tumor into one that is susceptible to T‑cell‑mediated immune attack, opening the door for new immunotherapy combinations and potentially improving outcomes for patients with this aggressive cancer.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Radiogenomics of clear‑cell renal cell carcinoma: Associations between CT imaging features and mutations